INTRODUCTION
Almost more than 90% drugs are orally
administered. Drug absorption sufficient and reproducible bioavailability, pharmacokinetic profile of
orally administered drug substances is highly dependent on solubility of that
compound in aqueous medium. More than 90% of drugs approved since 1995 have
poor solubility. It was estimated that 40% of active new chemical entities
(NCEs) identified in combinatorial
screening programs employed by many pharmaceutical companies are poorly water
soluble and not well absorbed after oral administration which can distract from
the drugs inherent efficacy. Drug absorption, sufficient and reproducible
bioavailability and/or pharmacokinetic profile in human are recognized today as
one of the major challenges in oral delivery of new drug substances. Orally administered drugs on the model list of
essential medicines of the World Health Organization (WHO) are assigned BCS
classification on the basis of data available in the public domain .[1]
BCS
(Biopharmaceutical classification system) based on drug solubility and
permeability characteristics.
|
Class II
Low solubility and
high permeability
|
Class I
High solubilit=y and
high
permeability
|
|
Class IV
Low solubility and low
Permeability
|
Class III
High solubility and low
permeability
|
Controlled released
tablet:-
Oral drug delivery method is the most
widely utilized routes for administration among all alternatives that have been
explored for systemic delivery of drug via various pharmaceutical products of
different dosage forms. Popularity of the route may be ease of administration
as well as traditional belief that by oral administration the drug is due to
the well absorbed into the food stuff ingested daily. Controlled release (C.R)
pharmaceutical products have gradually gained medical acceptance and popularity. Regulatory approval for marketing and their
pharmaceutics superiority and clinical benefits over immediate release
pharmaceutical products have been increasingly recognized. Modified release
oral dosage forms have brought new lease of life into drugs that have lost
market potential due to requirement of frequent dosing, dose related toxic effects
and gastro intestinal disturbances. [2,3]
Materials and methods:
Preparation of pH 1.2 acidic buffer solution:
50 ml of 0.2 M potassium chloride solution in a 200 ml volumetric flask was
taken added with 85.0 ml of 0.2 M
hydrochloric acid solution shaken for complete admixture. The final was
adjusted with distilled water.
Preparation of simulated gastric fluid (pH 1.2): Accurately
weighed 2.0 gm of sodium chloride and 3.2 gm of purified pepsin were completely
dissolved in 7.0 ml of hydrochloric acid and volume
was made up to 1000 ml by distilled water and the pH (1.2) was adjusted.
Preparation of
pH 5.8 Phosphate buffer solution: 50 ml of 0.2 M
potassium Dihydrogen phosphate solution was poured in a 200 ml volumetric flask
which was added with 3.6 ml of 0.2 M sodium
hydroxide solution and shaken for complete mixture. The final volume
was adjusted with distilled water.
Preparation of
simulated intestinal fluid (pH 5.8): Accurately
weighed 6.8 gm of monobasic potassium phosphate was dissolved in 250ml of
distilled water, 77 ml of 0.2 M sodium hydroxide and
500 ml of distilled waterwere added. 10.0 gm of pancreatin was added, and dissolved
finally diluted withdistilled water up to 1000 ml and pH 5.8 was adjusted.
Preparation of Carvedilol solution (stock) in the
presence of solubilizing agent: Two samples each
containing 1.0 mg of carvedilol was accurately weighed and transferred to 1000
ml volumetric flasks separately. 30ml of 10 %
(methanol &ethanol) & 20% solution of solubilizer in distilled
water were added and drug was dissolved in each flask. After complete
dissolution of drug, sufficient distilled waterwas used to make up the
volume.Similarly stock solutions of carvedilol were prepared incorporating
different solubilizing agent’s i.e urea, Nicotinamide, PEG 400, PEG
4000,Nicotinamide +Urea, Nicotinamide +PEG 400, Nicotinamide + PEG 4000, PEG
400+Urea, PEG4000 + PEG 400.The regression curves were obtained by plotting
absorbances vs concentrations (in each case) using respective blanks employed
in the processes concerned the concentration rang 0.5, 1.0, 1.5.2.0 and 2.5
mcg/ml of the drug.
Drug- excipient compatibility studies:
Compatibility study using FTIR Technique: Drug–excipient
compatibility study was carried out by FTIR (Shimadzu
Affinity-1)spectrophotometery. The mixture of drug and KBr (potassium
bromide) was ground into fine powder using mortar pestle and then
compressed into discs in a hydraulic press at a pressure of 75 kg/cm 2 . Each
KBr discs was scanned 45 times at a resolution of 2 cm -1 . The
characteristic peaks were recorded and compared with that obtained with
individual formulation.
Equilibrium solubility determination:
Solubility of Carvedilol in distilled water and buffer
system: The solubility of Carvedilol was carried
out in distilled water, acidic buffer (pH 1.2) and phosphate buffers (pH 5.8
& pH 6.8). The excess drug was added gradually to 30ml of each solvent
contained in 250 ml volumetric flask and shaken on
mechanicalshaker at room temperature for 12 hrs so that equilibrium solubility
can be achieved and solutions were allowed to equilibrate for 24 hrs. Then
after the solutions weretransferred into centrifuge tubes and centrifuged at
about 2000 rpm for 5 minutes and filtered through Whatman filter paper no. 5
Aliquots of the filtrate were suitably diluted. The diluted solutions were
analyzed at 241 nm against the reagent blank.
Preparation of solid
dispersion and Physical mixture:
For
preparation of solid dispersion containing Carvedilol and PEG 4000, PEG 400 in
the ratio of 1:2(w/w), 8.9 ml of PEG 400, 10 gm of Polyethylene glycol 4000 and
1 gm of Carvedilol were used. Minimum
(possible) quantity of methanolic solution (10%) at 80-85 o C contained
in a 250 ml beaker was used to dissolved PEG 400, Polyethylene glycol 4000.
Then Carvedilol was added to the beaker and a Teflon coated magnetic bead was
dropped in it. Stirring of magnetic bead in beaker was started using a hot
plate magnetic stirrer. Carvedilol got completely solubilized. Stirring was
continued till a semisolid was obtained in the beaker which was spread on watch glasses in thin
layers forquick drying. The watch glasses were kept in oven maintained at 60-65
o C for drying.When mass became pulverizable, it was triturated with the help of
pestle mortar andkept in oven for drying. After almost complete drying, the
powder of solid dispersionwas passed through sieve # 100 and kept for 6 days in
dessicator containing bluesilica gel. After this the solid dispersion powder
was stored in air tight bottles Similarly solid
dispersion of carvedilol and PEG 400, Polyethylene glycol 4000 [1:4,1:6
(w/w)].
Preparation of Physical
Mixtures:
To
prepare physical mixture containing carvedilol and PEG 4000 and PEG 400 in
ratio of 1:2 (w/w), accurately weighed
(1 gm) Carvedilol, 8.9 ml of PEG 400, 10 gm of Polyethylene glycol 4000 were
triturated intensely for 10 min using glass pestle mortar. Then the powder mass
was shifted through sieve #
100.Similarly physical mixtures of carvedilol and PEG 4000, PEG 400 in ratio of
[, 1:4 & 1:6 (w/w)] were prepared.
Evaluation of solid
dispersion and physical mixture:
Determination of drug content in prepared solid
dispersion and physical mixture: Powdered solid
dispersion /physical mixture containing Carvedilol equivalent to 10 mg was
accurately weighed and transferred to 100 ml volumetric flask. About 900 ml
distilled water was added and thecontent shaken to dissolved the formulation
completely. Finally the volume was adjusted with distilled water and the
absorbance of this solution was measured at 241 nm against respective reagent
blank. The drug content was determined using regression equation.
In-vitro dissolution studies of physical mixtures and
solid dispersion: In vitro dissolution
study was performed using USP type II apparatus (paddle type) at50 rpm using
distilled water as dissolution media maintained at temperature 37 ± 0.5 C.
Aliquots of dissolution media were withdrawn at specific time intervals
replacing with fresh media and filtered. The amount of drug dissolved was
determined by U.V. spectrophotometric analysis of withdrawn sample at 241 nm.
Selection of solid dispersion for further formulation
development:Based on the data of drug content and
the dissolution studies, a suitable solid dispersion was selected for further
formulation development (tablet dosage form).
Pre compression parameters:
Bulk density (D b ):It
is the ratio of total mass to the bulk volume of powder. It was measured by
pouring the weighed powder into a
measuring cylinder and the volume was noted. It was expressed in gm/cc and given by:
D b = M/ Vo
Where M= Mass of powder
Vo= Bulk volume of the powder
Tapped
density (Dt):It is the ratio of total mass of
powder to its tapped volume. The tapped volume was
measured by tapping the
powder to certain volume it was expressed in gm/cc given by:
Dt=
M/Vt
Where,
M= Mass of powder
Vt=
tapped volume of the powder.
Angle
of repose: The frictional forces in a loose
powder can be measured by the angle of repose (θ) as
the maximum angle
possible between the surface of a pile of powder and the horizontal plane
tan
θ= h/r
θ=tan
-1 (h/r)
h=
height in cm.
r=
radius
Carr’s
index (i):It indicated the ease with which a
material could be induced to flow and expressed in
percentage as given by
I=Dt-Db/Dt
× 100
Where,
Dt =tapped density of the powder.
Db=bulk
density of the powder.
Formulation of tablet:
Direct compression method: The
tablets were formulated employing direct compression method using single punch
tablet punching machine. Tablets were compressed directly from mixtures of the
drug and excipients without preliminary treatment like granulation.
Screening of excipients: Nine
trial batches of formulations were designed for screening of different type of release modifier polymer (controlled
released polymer).Based on the experiments designed to develop the
formulations. The tablet consisted of solid dispersion (equivalent to 12.5 mg
Carvedilol), The weight of tablets in each batch was kept constant. Effect of
various types of release modifier polymers(individual) and in combination with other,
on various tablet properties and in-vitro dissolution characteristic were
studied and discussed. Tablets were formulated using Carvedilol from its solid
dispersion with different excipients viz. Eudragit RS 100 & Ethyl
cellulose (release modifier), mannitol as diluents and magnesium stearate.
Formulation of controlled release tablets of
Carvedilol: Total nine batches are prepared using
different release modifier (polymers) alone and in combinations.
Formulation chart of
controlled release tablet of Carvedilol:
|
|
F1
|
F2
|
F3
|
F4
|
F5
|
F6
|
F7
|
F8
|
F9
|
|
Soliddispersion
(mg)
|
266.66
|
266.66
|
266.66
|
266.66
|
266.66
|
266.66
|
266.66
|
266.66
|
266.66
|
|
Eudragit RS 100
(mg)
|
40
|
80
|
120
|
-
|
-
|
-
|
40
|
80
|
60
|
|
Ethylcellulose
(mg)
|
-
|
-
|
--
|
40
|
80
|
120
|
80
|
40
|
60
|
|
Mannitol (mg)
|
89.36
|
49.30
|
9.30
|
89.30
|
49.30
|
9.30
|
9.30
|
9.30
|
9.30
|
|
Mg. stearate (mg)
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
|
Total weight (mg)
|
400
|
400
|
400
|
400
|
400
|
400
|
400
|
400
|
400
|
Post compression
evaluation parameters:
Hardness: The hardness of
the tablet was determined using a Monsanto hardness tester and expressed in
Kg/cm 2.
Friability (F):
The friability of the tablet was
determined using Roche Friabilator and expressed in percentage (%). 10 tablets
were initially weighted (W initial ) and transferred into the fraibilator
operated at 25 rpm for four min. The percentage friability was then calculated
the formula:
F=
W initial- W final/ W initial × 100
Weight variation: 20
tablets were selected at random and average weights were determined. Then
individual tablet was weighed and was compared with the average weight values.
Thickness:
The thickness of the tablets was measured by screw gauge and expressed in mm.
Uniformity of drug content:Ten
tablets were weighed and powdered in a mortar. Accurately weighed powdered
samples (equivalent to 42.275 mg of Carvedilol) was transferred to a 100 ml
volumetric flask and dissolved in 75ml methanol. Finally, the volume was made
to 100 ml with methanol. This solution was suitably diluted with pH 1.2 acidic
buffer and the absorbance was measured at 241nm. The concentration was
estimated in triplicate.
In vitro dissolution studies: In
vitro drug release was carried out for all batches by using USP (TDL-06L) type
I dissolution test apparatus. The dissolution studies were
carried out in pH 1.2 acidic buffer for 2 hrs. followed by pH 5.8 for 4 hrs.
& pH 6.8 phosphate buffer up to 12 hrs. Similarly the parallel
evaluation of dissolution parameter were conducted in simulated
gastric (pH 1.2) accomparsied by simulated intestinal fluid (pH5.8
& ph 6.8) sequentially. The tablet was kept into the basket. The
temperature and stirring rate were
maintained at 37 ± 5 o C and 100 rpm respectively. 5 ml sample were withdrawn
in each case, diluted suitably and analyzed for the drug content
spectrophotometrically at λ max 241 nm using dissolution media (pH 1.2, pH5.8
& 6.8 phosphate buffer, simulated gastric fluid (pH 1.2) and simulated
intestinal fluid (pH 5.8 and pH 6.8 ) as blank.
Comparison of dissolution profile: Data
obtained from the in vitro release of carvedilol matrix tablet formulation
(F1-F9)were fitted to various kinetic equations i.e. as zero order, first
order, Higuchi model and Korsmeyer-Pappas model.
Stability study: The
stability study of drug loaded matrix tablet was carried out for a period of 90
days at 40±2 o C temperature and relative humidity of 75±5% using stability
chamber. Samples was collected after 90 days and evaluated for drug release.
RESULT AND DISCUSSION
Pre-formulation
parameters for raw material: Pre-formulation parameter
like foreign matter, moisture, water soluble extractive, alcohol soluble
extractive, ash value, acid insoluble ash value was determined for herbs used
in formulation.
Determination of melting
point: The melting point of Carvedilol was found to be 115 C.
UV
spectrophotometric scan of carvedilol: -
The stock solution of
carvedilol was prepared using acidic buffer (pH 1.2). A randomly selected
sample containing the drug (5µg/ml) was scanned between 200-400nm. The λ max
was found to be 241nm.
Validation
of λ max : -The samples containing different
concentrations (5-25µg/ml) of the drug were run and overlain spectra describing
the reproducibly of the λ max (earlier scanned) was obtained that confirmed and
validated the process.
FTIR
Analysis: IR absorption spectrum of Meloxicam was
obtained by means of KBr pellet technique and peaks attained were compared with the reference as depicted in
table 4.3, which demonstrate the distinct peaks of some functional groups.
Similarly IR spectrum of drug and excipients i.e. Niacinamide, Anhydrous Sodium
Citrate, Croscarmellose Sodium, Sodium Benzoate and Sodium Salicylate were
obtained.
Pre-compression
parameters for formulations of factorial designs: Pre
compression parameters of diverse formulation blends (F1-F9) were calculated.
Post-compression parameters of factorial designed formulations Post compression
parameters i.e. Thickness, Hardness, Weight Variation, Friability and D.T for
samples of diverse formulation (F1-F9), were calculated.
Post-compression
parameters for formulations of factorial
designs:The samples from each batch of tablet
formulation were evaluated for post compression parameters such as thickness,
weight variation, hardness, friability & disintegration time.
Post
–compression parameter of tablets: Post
compression parameter of formulation F 1 to F 9
|
|
Thickness (mm)
|
Weight
variation
|
Hardness (kg/cm 2 )
|
Friability (%)
|
Drug
content(%)
|
|
F1
|
2.48
|
Pass
|
5.30
|
0.975
|
94.00
|
|
F2
|
2.51
|
Pass
|
5.40
|
0.974
|
93.95
|
|
F3
|
2.51
|
Pass
|
5.90
|
0.974
|
92.11
|
|
F4
|
2.53
|
Pass
|
4.90
|
0.950
|
90.88
|
|
F5
|
2.51
|
Pass
|
5.08
|
0.875
|
90.26
|
|
F6
|
2.50
|
Pass
|
5.20
|
0.990
|
92.75
|
|
F7
|
2.51
|
Pass
|
6.00
|
0.977
|
95.58
|
|
F8
|
2.33
|
Pass
|
6.40
|
0.992
|
97.10
|
|
F9
|
2.42
|
pass
|
6.60
|
0.995
|
95.24
|
In-vitro
dissolution rate studies of Formulation F 1 - F 9 in acidic buffer (pH1.2) and
5.8 pH & pH 6.8 phosphate buffer:
|
Sr.
no
|
Time
(minutes)
|
F1(%drug release)
|
F2(%drug release)
|
F3(%drug release)
|
|
1
|
0
|
0.000
|
0.00
|
0.00
|
|
2
|
30
|
12.960
|
13.680
|
9.900
|
|
3
|
60
|
35.412
|
27.676
|
22.255
|
|
4
|
120
|
43.577
|
41.074
|
26.584
|
|
5
|
180
|
57.509
|
49.695
|
29.731
|
|
6
|
240
|
62.653
|
52.676
|
46.699
|
|
7
|
300
|
65.748
|
59.359
|
51.259
|
|
8
|
360
|
76.565
|
64.196
|
56.018
|
|
9
|
420
|
80.131
|
69.578
|
61.638
|
|
10
|
480
|
90.382
|
78.450
|
67.921
|
|
11
|
540
|
94.165
|
82.036
|
75.788
|
|
12
|
600
|
94.249
|
92.729
|
84.042
|
|
13
|
660
|
94.503
|
92.789
|
86.930
|
|
14
|
720
|
94.504
|
92.789
|
88.967
|
Fig: Zero order drug release
of F 1, F 2 & F 3 batches in in acidic buffer (pH 1.2) and pH 5.8
and pH 6.8 phosphate buffer:
Fig: First order drug
release of F 1, F 2 & F 3 batches in in acidic buffer (pH 1.2) and pH
5.8
and pH 6.8 phosphate buffer:
Fig: First order drug
release of F 4, F 5 & F 6 batches in in acidic buffer (pH 1.2) and pH
5.8
and pH 6.8 phosphate
buffer:
CONCLUSION:
So far the analysis was
carried out on “Formulation and evaluation of controlled release tablets of
carvedilol using hydrotropic technique” revealed following conclusions:
FTIR & uv
spectrometric scan of carvedilol analysis were carried out. The characteristic
peaks of the drug were compared in pure form with those obtained with
drug-excipient combinations which remained almost the same of pure drug and that of drug-excipients
combinations resulted approximately
equivalent Rf values. Conclusively carvedilol was found to be compatible with excipients used tablet formulations.
Equilibrium solubility
testing was carried out and its results concluded that the diluted solution
were analyzed at 241nm against reagent blank relative to its aqueous solubility
by using hydrotropy.
Among the trial batches
of formulations, optimized results were attained with T3, which was further
integrated into factorial design and developed as (F1-F9). other parameters of
pre-compression calculated by the powdered blends were Bulk Density , Tapped
Density , Angle of Repose , Carr's Index and Hausner,s Ratio . These
formulations were exposed to different evaluation parameters for the analysis
of post-compression parameters and the results were implicated:
Hardness , Thickness ,
Friability , Weight variation, Disintegration time and In-vitro drug release determination. The In-vitro release
of drug was carried out by using USP(TDL-06L)TYPE 1 dissolution test apparatus.
The stability test studies was conducted with optimized formulation in
compliance with the ICH guidelines under officially defined conditions that
showed that theformulations were stable and thus met the dose conformity
criterion.
The present worker
proposed that such a concept of formulation could be extended to drugs of
various classifications lighting the way for prospective researchers to improve
aqueous solubility and to devise more oral dosage forms with potential enhanced
bioavailability.
REFERENCES:
1.
Sandhiya jatwani, et al. “ An Overview On
Solubility Enhancement Techniques For Poorly Soluble Drugs And Solid Dispersion
As An Eminent Strategic Approach” IJPSR, 2012;vol.3(4):942-956.
2.
C.V.S.
Subramanyum, “ Text of biopharmaceutics and pharmacokinetics” published by
vallabhprakashan, first edition-2010,page no. 171-173.
3.
Martin Alfred, et al. “ physical pharmacy” 3rd
edition, published by Varghese publishing house, 1991 page no. 272-273.
4.
Michael E. Aulton, “ Aulton’s
pharmaceutics the design and manufacture of medicines” pubilished by Churchill
livingstone Elsevier, third edition, page no. 22-23.
5.
Jinal N. Patel, et al. 2012, “Techniques
to improve the solubility of poorly soluble drugs” IJPLS, Vol. 3, Issue 2:
Feb.: 2012, 1459-1469.
6.
Swati Aggarwal, et al , “Solubility And
Its Enhancement Techniques Of Poorly Soluble Drugs” international journal of
universal pharmacy and life sciences, 2012, (ISSN): 2249-6793
7.
Ahmad Zaheer, et al, “Solubility
Enhancement Of Poorly Water Soluble Drugs: A Review” IJPT | March-2011 | Vol. 3
| Issue No.1 | 807-823
8.
D. Akhilesh, et al, “ enhacement of
solubility by complexation with cyclodextrin and nanocrystallation” I RJP 2012,3(5)
9.
Gulshan Chhabra, et al, “enhancement of
solubility and dissolution rate of a poorly water soluble drug using single and
double hydrophilization approach”int j pharm pharm sci, vol 4, issue 1,
395-405.
10.
Sushama Talegaonkar,et al,
“Microemulsions: A Novel Approach to Enhanced Drug Delivery” Recent Patents on
Drug Delivery & Formulation 2008, 2, 238-257
11.
Jyotsana Madan, et al; “Emulsion based drug
delivery system” Indian Journal of Novel Drug delivery 3(1), Jan-Mar, 2011,
2-8.
12.
Aungst, B. J. (1993). Novel formulation
strategies for improving oral bioavailability of drugs with poor membrane
permeation or presystemic metabolism. Journal of pharmaceutical sciences,
82(10), 979-987.
13.
Burcham, D. L., Maurin, M. B., Hausner, E.
A., & Huang, S. M. (1997).Improved oral bioavailability of the
hypocholesterolemic DMP 565 in dog following oral dosing in oil and glycol
solutions. Biopharmaceutics & drug disposition, 18(8), 737-742
14.
Liu, R. (2000). Water-insoluble drug
formulation. CRC press.
15.
Gong,
Y., Grant, D. J., & Brittain, H. G. (2007). Principles of solubility.In
Solvent systems and their selection in pharmaceutics and biopharmaceutics (pp.
1-27). Springer, New York, NY.
16.
Letcher, T. M. (Ed.). (2007). Thermodynamics,
solubility and environmental issues. Elsevier.
17.
Raut, N. A. (2018). Enhancement of aqueous
solubility and permeability of poorly water soluble drug. Pharma Focus Asia,
Issue, (29).
18.
Moore, M. D., & Wildfong, P. L. (2009).
Aqueous solubility enhancement through engineering of binary solid composites:
pharmaceutical applications. Journal of Pharmaceutical Innovation, 4(1), 36-49.
19.
Sachan, N. K., Bhattacharya, A., Pushkar,
S., & Mishra, A. (2014).
20.
Biopharmaceutical classification system: A
strategic tool for oral drug delivery technology. Asian Journal of
Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 3(2)
21.
Solubility,Wikipedia,the free
encyclopedia,science daily/solubility.htm 10. Martin, A. (1993). Physical
pharmacy: physical chemical principles in the pharmaceutical sciences. BI
Waverly. Pvt Ltd.
22.
Gibson, M. (2001). Pharmaceutical
preformulation and formulation. Drugs and the pharmaceutical sciences, 199,
199.
23.
Pharmacopoeia, I. (1996). Government of India,
ministry of health and family welfare. Delhi: Controller of Publications,
2(35), 448.